Inflammatory demyelinating diseases of the central nervous system

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) because the unknown etiology of some of them, and sometimes known as borderline forms of multiple sclerosis,[1] is a collection of multiple sclerosis variants, sometimes considered different diseases,[2][3] but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course.[4][5]

Multiple sclerosis for some people is a syndrome more than a single disease.[6] As of 2019 three auto-antibodies have been found in atypical MS giving birth to separate diseases: Anti-AQP4 diseases, Anti-MOG and Anti-NF spectrums.[7] Also a LHON-associated MS[8] has been reported, as well as the medication-induced anti-TNF spectrum (which cannot be distinguished from natural MS with the current knowledge) can be included here.[9][10][11][12][13][14][15]

The subject is under intense research and the list of MS autoantibodies is expected to grow in the near future[16][17][18]

Separated variants[edit]

Several previous MS variants have been recently separated from MS after the discovery of a specific auto-antibody. Those autoantibodies are currently anti-AQP4, anti-MOG and some anti-Neurofascins.[19]

The pathogenic mechanism is usually not related to the clinical course. Therefore, one given pathogenic underlying condition can yield several clinical diseases, and one disease can be produced by several pathogenic conditions.

These conditions can appear as Neuromyelitis optica (NMO), and its associated "spectrum of disorders" (NMOSD), currently considered a common syndrome for several separated diseases[20] but with some still idiopathic subtypes. Some researchers think that there could exist an overlapping between Anti-NMDA receptor encephalitis cases and neuromyelitis optica or acute disseminated encephalomyelitis.[21]

Anti-AQP4 spectrum[edit]

See Anti-AQP4 diseases

Originally found in neuromyelitis optica, this autoantibody has been associated with other conditions. Its current spectrum is as following:

Anti-MOG spectrum[edit]

See Anti-MOG associated encephalomyelitis

Anti-MOG associated spectrum, often clinically presented as an anti-MOG autoimmune encephalomyelitis,[25][26] but can also appear as negative NMO or atypical multiple sclerosis.[27]

The presence of anti-MOG autoantibodies has been associated with the following conditions[28]

  • Some cases of aquaporin-4-seronegative neuromyelitis optica: NMO derived from an antiMOG associated encephalomyelitis,[29]
  • Some cases of acute disseminated encephalomyelitis, specially the recurrent ones (MDEM)[30]
  • Some cases of McDonalds-positive multiple sclerosis[28][31][27][32]
  • isolated optic neuritis or transverse myelitis[28]
  • Recurrent optic neuritis. The repetition of an idiopatic optic neuritis is considered a distinct clinical condition, and it has been found to be associated with anti-MOG autoantibodies[33]

The anti-mog spectrum in children is equally variated: Out of a sample of 41 children with MOG-antibodies 29 had clinical NMOSD (17 relapsing), 8 had ADEM (4 relapsing with ADEM-ON), 3 had a single clinical event CIS, and 1 had a relapsing tumefactive disorder. Longitudinal myelitis was evident on MRI in 76[percent]. It has also been noted that percentage of children with anti-mog antibodies respect a demyelinating sample is higher than for adults[37]

Some NMO patients present double positive for autoantibodies to AQP4 and MOG. These patients have MS-like brain lesions, multifocal spine lesions and retinal and optic nerves atrophy.[38]

Anti-neurofascin spectrum[edit]

See Anti-neurofascin demyelinating diseases

Some anti-neurofascin demyelinating diseases were previously considered a subtype of Multiple Sclerosis but now they are considered a separate entity, as it happened before to anti-MOG and anti-AQP4 cases. Around 10% of MS cases are now thought to be anti-Neurofascin disease in reality.[39]

Anti-neurofascin autoantibodies have been reported in atypical cases of MS and CIDP, and a whole spectrum of Anti-neurofascin demyelinating diseases has been proposed.[40]

Some cases of CIDP are reported to be produced by auto-antibodies against several neurofascin proteins. These proteins are present in the neurons and four of them have been reported to produce disease: NF186, NF180, NF166 and NF155.[40]

Antibodies against Neurofascins NF-155 can also appear in MS[41] and NF-186 could be involved in subtypes of MS[42] yielding an intersection between both conditions.

Summarising, autoantibodies against several neurofascins can produce MS: neurofascin186 (NF186), neurofascin155 (NF155), contactin 1 (CNTN1), contactin associated protein 1 (CASPR1) and gliomedin. All of them nodal and paranodal proteins.[40]

Anti-TNF spectrum[edit]

Several anti-TNF drugs like adalimumab[9][10] are commonly prescribed by a number of autoimmune conditions. Some of them have been reported to produce a CNS-demyelination compatible with, and by current knowledge indistinguishable from, standard MS.[11][12] Several other monoclonal antibodies like pembrolizumab,[13] nivolumab [14] and infliximab[15] have been also reported to produce MS artificially. Nevertheless, it is not so similar as reported in the previous references.[43]

This has given birth to the Anti-TNF-α therapy-associated demyelinating disorders. The reactions have been diverse according to the source of the disease.[11][12][14] Some of these cases can be classify as ADEM, using the confluent demyelination as barrier between both conditions.[44]

In most cases, the damage fulfills all pathological diagnostic criteria of MS and can therefore be classified as MS in its own right. The lesions were classified as pattern II in the Lassman/Lucchinetti system. Some lesions also showed Dawson fingers,[12] which is supposed to be a MS-only feature.

These recent problems with artificial anti-TNF-α autoimmunity also point to the possibility of tumor necrosis factor alpha involvement in some multiple sclerosis variants.

LHON-associated MS[edit]

Also a previous subtype of MS associated to LHON has been described (LHON-MS)[8] It is a presentation of LHON with MS-like CNS damage.

It used to satisfy McDonalds definition for MS, but after demonstration that LHON can produce this kind of lesions, the "no better explanation" requirement does not hold anymore. It is not due to auto-antibodies, but to defective mitochondria instead.[45]

The symptoms of this higher form of the disease include loss of the brain's ability to control the movement of muscles, tremors, and cardiac arrhythmia.[46] and the lack of muscular control[47]

Variants still idiopathic[edit]

Apart of the previously cited spectrums (Anti-AQP4 diseases, Anti-MOG, Anti-NF and anti-TNF spectrums) there is a long list of MS variants, with possibly different pathogenesis, which are still idiopathic and considered inside the MS-spectrum.

Pseudotumefactive variants[edit]

Most atypical variants appear as tumefactive or pseudotumefactive variants (lesions whose size is more than 2 cm (0.79 in), with mass effect, oedema and/or ring enhancement)[48][49] Some cases of the following have shown anti-MOG auto-antibodies and therefore they represent MS cases only partially.

  • Acute disseminated encephalomyelitis or ADEM, a closely related disorder in which a known virus or vaccine triggers autoimmunity against myelin. Around 40% of the ADEM cases are due to an "anti-MOG associated encephalomyelitis".[50] It includes Acute hemorrhagic leukoencephalitis, possibly a variant of Acute disseminated encephalomyelitis
  • Marburg multiple sclerosis, an aggressive form, also known as malignant, fulminant or acute MS, currently reported to be closer to anti-MOG associated ADEM than to standard MS.[51] and is sometimes considered a synonym for Tumefactive multiple sclerosis[52]
  • Balo concentric sclerosis, an unusual presentation of plaques forming concentrenic circles, which can sometimes get better spontaneously.
  • Schilder disease or diffuse myelinoclastic sclerosis: is a rare disease that presents clinically as a pseudotumoural demyelinating lesion; and is more common in children.[53][54]
  • Solitary sclerosis: This variant has been recently proposed (2012) by Mayo Clinic researchers.[55] though it was also reported by other groups more or less at the same time.[56][57] It is defined as isolated demyelinating lesions which produce a progressive myelopathy similar to primary progressive MS.

Atypical location variants[edit]

Also the location of the lesions can be used to classify variants:

  • Myelocortical multiple sclerosis (MCMS), proposed variant with demyelination of spinal cord and cerebral cortex but not of cerebral white matter [58] Several atypical cases could belong here. See the early reports of MCMS<[59][60]
  • Opticospinal MS or Optic-spinal MS (OSMS): Old OSMS cases are now considered inside the NMO spectrum, but this does not apply to anti-AQP4 negative cases.[61] After the discovery of anti-AQP4 autoantibodies it was found that some cases of OSMS were AQP4-negative, and therefore, they are considered real MS cases. OSMS has its own specific immunological biomarkers[62] The whole picture is under construction and several reports exists about overlapping conditions.
  • Pure spinal multiple sclerosis: Patients with clinical and paraclinical features suggestive of cord involvement of multiple sclerosis (MS)-type albeit not rigidly fulfilling the McDonald criteria[63] Some inflammatory conditions are associated with the presence of scleroses in the CNS.[64] Optic neuritis (monophasic and recurrent) and Transverse myelitis (monophasic and recurrent)
  • LHON associated MS (LHON-MS), a presentation of LHON with MS-like CNS damage, and therefore a subtype of MS according to McDonalds definition.[8]

Atypical OCB variants[edit]

Also different classifications by body fluid biomarkers is possible:

  • Oligoclonal negative MS: Some reports point to the possibility of a different pathogenesis[65] They represent around 5% of the cases[66] which is suspected to be immunogenetically different.[67] Their evolution is better than standard MS patients,[68]
  • Oligoclonal IgM positive MS, with immunoglobulin-M Bands (IgM-Bands), which accounts for a 30-40% of the MS population and has been identified as a predictor of MS severity.[69] It has been reported to have a poor response to interferon-beta but a better response to glatimer acetate instead[70]
  • OCB's types: OCBs are made up of activated B-cells. It seems that the molecular targets for the OCB's are patient-specific.[71]

Radiologically atypical variants[edit]

Inside well defined MS (Lesions disseminated in time and space with no other explanation) there are atypical cases based in radiological or metabolic criteria. A four-groups classification has been proposed:[72]

Other radiological classification of atypical lesions proposes the following four subtypes:[74]

  • infiltrative
  • megacystic
  • Baló-like
  • ring-like lesions

Atypical clinical courses[edit]

In 1996, the US National Multiple Sclerosis Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis (ACCTMS) standardized four clinical courses for MS (Remitent-Recidivant, Secondary Progressive, Progressive-Relapsing and Primary progressive). Later,[75]

Some reports state that those "types" were artificially made up trying to classify RRMS as a separate disease so that the number of patients was low enough to get the interferon approved by the FDA under the orphan drugs act.[75] Revisions in 2013 and 2017 removed the Progressive-Relapsing course and introduced CIS as a variety/course/status of MS, establishing the actual classification (CIS, RRMS, SPMS and PPMS). Nevertheless, these types are not enough to predict the responses to medications and several regulatory agencies use additional types in their recommendations lide Highly active MS, Malignant MS, Aggressive MS or Rapidly progressive MS.[76]

Highly Active MS[edit]

As of 2019, HAMS is defined as an RRMS phenotype with one or more of the following characteristics:[76]

  1. DSS scale of 4 points at 5 years of onset of the disease
  2. Multiple relapses (two or more) with incomplete recovery in the ongoing year
  3. More than 2 brain magnetic resonance imaging (MRI) studies demonstrating new lesions or increase in the size of the lesions in T2, or lesions that enhance with gadolinium despite treatment (Clinical case 1 and 2).
  4. No response to treatment with one or more DMTs for at least one year.

There is a group of patients who have defined clinical and radiological risk factors that predict a behavior of greater risk of conversion to HAMS, without having the diagnostic criteria of HAMS in a first clinical attack have predictors of high risk.

Some other previous authors have used other definitions like:

  • High activity according to 2017 definition of activity
  • Rapid accumulation of physical and cognitive deficit, despite treatment with DMT's.
  • Being eligible for immunoablative therapy followed by autologous haematopoietic stem cell transplantation (aHSCT) because of a) the failure of conventional treatment, b) frequent and severe (disabling) relapses, or c) MRI activity (new T2 or gadolinium-enhancing lesions).

Malignant MS[edit]

See malignant multiple sclerosis

Occasionally, the term ‘malignant’ MS (MMS) has been used to describe aggressive phenotypes of MS, but this is another ambiguous term that—despite wide usage—means different things to different people.

In 1996, the US National MS Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis, “malignant MS” was also included, namely, “disease with a rapid progressive course, leading to significant disability in multiple neurologic systems or death in a relatively short time after disease onset.”

Many authors reserve the term malignant for fulminant forms of MS that deteriorate so rapidly from the outset as to be almost monophasic, and result in death within months to a few years. One such example is the Marburg variant of MS, which is classically characterized by extensive necrotic and/or tumefactive lesions with mass effect.

Interestingly, despite recent (and increasing) emphasis on early detection of patients with aggressive MS, the original definition of MMS was not modified by the NMSS Advisory Committee in its latest publication in 2013 (Lublin et al., 2014).

Aggressive MS[edit]

Common to all definitions is the early, unexpected acquisition of disability followed by frequent relapses and highly active disease seen on MRI.

One definition can be based on EDSS score and the time to develop secondary progressive MS (SPMS) (Menon et al., 2013).

No consensus exists on the speed of progression or degree of disability sufficient for aggressive MS, but we can assume that reaching an EDSS score of 6 points probably represents an upper limit beyond which the risk-benefit ratio for an aggressive treatment is unfavourable.

Pragmatically, AMS has been defined as any type of MS that is associated with repeated severe attacks and accelerated accrual of disability—put more simply, ‘rapidly progressive’ MS (See below)

Rapidly progressive multiple sclerosis[edit]

This kind of MS was previously reported to behave different that the standard progressive course,[77] being linked to Connexin 43 autoantibodies with pattern III lesions (distal oligodendrogliopathy)[78] and being responsive to plasma exchange[79]

In very rapidly progressive multiple sclerosis the use of immunosuppressive therapy (mitoxantrone/cyclophosphamide), rituximab, autologous haematopoietic stem cell therapy or combination therapy should be considered carefully.[80]

Under research[edit]

Some auto-antibodies have been found consistently across different MS cases but there is still no agreement on their relevance:

  • Anti-kir4.1: A KIR4.1 multiple sclerosis variant was reported in 2012[81] and later reported again,[82] which could be considered a different disease (as Devic's disease did before), and can represent up to a 47% of the MS cases
  • Anoctamin 2: Auto-antibodies against anoctamin-2 (ANO-2), one of the ion-channel proteins, have been reported consistently since 2013[83]
    • This finding is not universal. Most of the MS patients do not show auto-antibodies against ANO-2. Therefore, this points toward an ANO2 autoimmune sub-phenotype in MS.[84]
    • Later reports point towards a mimicry between ANO-2 and EBV-EBNA-1 protein[85]
  • Anti-NMDAR autoantibodies: There is an overlap between cases of Anti-NMDA receptor encephalitis and MS, NMO and ADEM.[21] It also could be a confusion with Anti-NMDA receptor encephalitis in the early stages[86] but there are also anti-NMDAR reported cases that evolve to McDonalds MS[87]
  • Anti-Flotilin spectrum: The proteins Flotillin 1 and flotillin 2 have been recently identified as target antigens in some patients with multiple sclerosis. First 14 cases were reported together in the first report, and 3 new cases were reported later inside a cohort of 43 patients.[88]
  • Mutations in GJB1 coding for connexin 32, a gap junction protein expressed in Schwann cells and oligodendrocytes, that usually produce Charcot-Marie-Tooth disease. In some cases also MS (as defined by McDonalds criteria) can appear in these patients.[89]
  • Also an OPA1 variant [90] exists.
  • There exist some reports by Drs. Aristo Vojdani, Partha Sarathi Mukherjee, Joshua Berookhim, and Datis Kharrazian of an aquaporin-related multiple sclerosis, related to vegetal aquaporin proteins.[91]
  • Auto-antibodies against histones have been reported to be involved.[92]
  • Anti-AQP1 could be involved in atypical MS and NMO[93]
  • N-type calcium channel antibodies can produce cognitive relapses mimicking MS related cognitive decline, and may coexist with MS.[94]
  • MLKL-MS: Mixed lineage kinase domain like pseudokinase (MLKL) related MS - A preliminary report has pointed out evidence of a novel neurodegenerative spectrum disorder related to it.[95]

Other auto-antibodies can be used to stablish a differential diagnosis from very different diseases like Sjögren syndrome which can be separated by Anti–Calponin-3 autoantibodies.[96]

The correlation between this genetic mutation and MS was challenged but in 2018 has been replicated by an independent team.[97] Notice that this results do not refer to general MS.

In general, NMO-like spectrum without known auto-antibodies is considered MS. Principal component analysis of these cases show 3 different kinds of antibody-negative patients. The metabolite discriminators of RRMS and Ab-NMOSD suggest that these groupings have some pathogenic meaning.[98]

As MS is an active field for research, the list of auto-antibodies is not closed nor definitive. For example, some diseases like Autoimmune GFAP Astrocytopathy or variants of CIDP that affects the CNS (CIDP is the chronic counterpart of Guillain–Barré syndrome) could be included. Autoimmune variants peripheral neuropathies or progressive inflammatory neuropathy could be in the list assuming the autoimmune model for MS, together with a rare demyelinating lesional variant of trigeminal neuralgia[99] and some NMDAR Anti-NMDA receptor encephalitis[51]

Venous induced demyelination has also been proposed as a hypothetical MS variant produced by CCSVI, Susac's syndrome and Neuro-Behçet’s disease(MS has an important vascular component[100]), myalgic encephalomyelitis (aka chronic fatigue syndrome).[101] Also leukoaraiosis can produce lesions disseminated in time and space. Maybe two sub-conditions of Leukodystrophy: Adrenoleukodystrophy and Adrenomyeloneuropathy could be in the list.

Genetic types[edit]

Different behaviour has been reported according to the presence of different HLA genes.

HLA DRB3*02:02 patients[edit]

In HLA DRB3 cases, autoimmune reactions against the enzyme GDP-L-fucose synthase has been reported[102][103] The same report points that the autoimmune problem could derive from the gut microbiota.

HLA-DRB1*15:01 has the strongest association with MS.[104]

HLA-DRB1*04:05, HLA-B*39:01, and HLA-B*15:01 are associated with independent MS susceptibility and HLA-DQβ1 position 9 with phenylalanine had the strongest effect on MS susceptibility.[104]

Another possible type is one with auto-antibodies against GDP-L-fucose synthase. In HLA-DRB3*02:02 patients, autoimmune reactions against the enzyme GDP-L-fucose synthase has been reported[102][103] The same report points that the autoimmune problem could derive from the gut microbiota.

Rapidly progressive multiple sclerosis[edit]

See malignant multiple sclerosis

This is a specially aggressive clinical course of progressive MS[105] that has been found to be caused by a special genetic variant. It is due to a mutation inside the gene NR1H3, an arginine to glutamine mutation in the position p.Arg415Gln, in an area that codifies the protein LXRA.[106]

Primary progressive variants[edit]

Some researchers propose to separate primary progressive MS from other clinical courses. PPMS, after recent findings seem to point that it is pathologically a very different disease.[107][108][109][110]

Some authors think since long ago that primary progressive MS should be considered a disease different from standard MS,[111][112] and it was also proposed that PPMS could be heterogeneous[113]

Clinical variants have been described. For example, Late Onset MS.[114] Since 2016, a special clinical variant of "rapidly progressive" MS has been found to be different from RRMS and other kinds of PPMS.[105] It is due to a mutation inside the gene NR1H3, an arginine to glutamine mutation in the position p.Arg415Gln, in an area that codifies the protein LXRA.


For the rest of the progressive cases, it has been found that the lesions are diffuse instead of the normal focal ones,[115] and are different under MR spectroscopy.[116] RRMS and PPMS patients also show differences on the retinal layers yields examined under OCT.[117]

Some authors have proposed a dual classification of PPMS, according to the shape of edges of the scars, in MS-like and ADEM-like[118] Proteomic analysis have shown that two proteins, Secretogranin II and Protein 7B2, in CSF can be used to separate RRMS from PPMS[119]

Recently, the hypothesis of PPMS being apart from RRMS/SPMS is taken further credibility due that it was shown that CSF from PPMS patients can carry the disease to other animals, producing neurodegeneration in mice[107] and that Normal Appearing White Matter (NAWM) structure is also different[120]

The predominant lesions in PPMS are slowly expanding lesions with T cells, microglial, and macrophage-associated demyelination in close similar to pattern I demyelination[121]

As of 2019 it has been found that the profile of T-cells is different in PPMS and SPMS[122]

Clinical situations inside standard MS[edit]

MS can be considered among the acquired demyelinating syndromes with a multiphasic instead of monophasic behaviour.[123] Multiple sclerosis has a prodromal stage in which an unknown underlying condition, able to damage the brain, is present, but no lesion has still developed.

MS is usually classified in clinical types, though they are unrelated to the underlying pathology. Some critical reports say that the current "types" were artificially made up, just to treat RRMS as a separate disease. In this way the number of patients was low enough to enter the orphan drugs act, and get the interferon approved by the FDA under this schema.[124] Recent reviews state that all types are a mixture of inflammation and neurodegeneration, and that all types should be considered the same disease.[125]

Other possible clinical courses are:

Preclinical MS: CIS and CDMS[edit]

The first manifestation of MS is the so-called Clinically isolated syndrome, or CIS, which is the first isolated attack. The current diagnosis criteria for MS do not allow doctors to give an MS diagnosis until a second attack takes place. Therefore, the concept of "clinical MS", for an MS that can be diagnosed, has been developed. Until MS diagnosis has been established, nobody can tell whether the disease one is dealing with is MS.

Cases of MS before the CIS are sometimes found during other neurological inspections and are referred to as subclinical MS.[126] Preclinical MS refers to cases after the CIS but before the confirming second attack.[127] After the second confirming attack the situation is referred to as CDMS (clinically defined multiple sclerosis).[128]

CIS itself is sometimes considered itself as a disease entity, different from MS. Even if they share the same underlying condition CIS is not MS given that it lacks the presence of lesions.[129] Approximately 84% of the subjects with CIS experience a second clinical demyelinating event and are diagnosed with clinically definite MS (CDMS) within 20 years.

RIS, subclinical and silent MS[edit]

See also Radiologically isolated syndrome

Silent MS has been found in autopsies before the existence of MRI[130] showing that the so-called "clinical definitions" cannot be applied to around 25% of the MS cases.[131] Currently a distinction is made between "silent" and subclinical.

In absence of attacks, sometimes a radiological finding suggestive of demyelination (T2 hyperintensities[132]) can be used to establish a pre-diagnosis of MS. This is often named "Radiologically Isolated Syndrome" (RIS). Cases before the first attack or CIS are subclinical in the sense that they do not produce clinical situations.

If a second radiological event appears without clinical consequences, the clinical situation is named "Silent MS" (Okuda criteria).[133] Anyway, it is reported that all MS cases have an active subclinical phase before the CIS[134]

It has been noted that some aspects of the MS underlying condition are present in otherwise healthy MS patients' relatives,[135] suggesting a wider scope for the "silent MS" term.

In these cases Interleukin-8 is a risk for clinical conversion.[136] It has also been proposed that always exists a subclinical phase in the beginning of every MS case, during which the permeability of the BBB can be used for diagnosis[137]

It is also under investigation whether MS has a prodrome, i.e., a preliminary stage in which the disease exists with non-specific symptoms. Some reports point to a prodrome of several years for RRMS and decades for PPMS.[138]

Aggressive multiple sclerosis[edit]

Relapsing-Remitting MS is considered aggressive when the frequency of exacerbations is not less than 3 during 2 years. Special treatment is often considered for this subtype.[139] According to these definition aggressive MS would be a subtype of RRMS. (See above)

Other authors disagree and define aggressive MS by the accumulation of disability, considering it as a rapidly disabling disease course[140] and therefore inside PPMS.

The aggressive course is associated to grey matter damage and meningeal inflammation, and presents a special intrathecal (meninges and CSF) inflammatory profile.[141]

After the 2016 revision of the MS phenotypes, it is called Highly active multiple sclerosis[142]

Mitoxantrone was approved for this special clinical course. Some reports point to Alemtuzumal being beneficial[143]

Pediatric and pubertal MS[edit]

MS cases are rare before puberty, but they can happen. Whether they constitute a separate disease is still an open subject. Anyway, even this pubertal MS could be more than one disease, because early-onset and late-onset have different demyelination patterns[144]

Pediatric MS patients tend to have active inflammatory disease course with a tendency to have brainstem / cerebellar presentations at onset. Due to efficient repair mechanisms at early life, pediatric MS patients tend to have longer time to reach EDSS 6 but reach it at earlier age.[145]

An iron-responsive variant of MS has been reported in children.[146]

Controversy for the definition[edit]

Given that the etiology of MS is unknown, the current definitions of MS are all based on its appearance. The most commonly used definition, the McDonald criteria, requires just the presence of demyelinating lesions separated in space and time, together with the exclusion of every known demyelinating condition.

This unspecific definition has been criticized. For some people this has turned MS into a heterogeneous condition with several underlying problems.[147] Besides, the complementary problem also exists. Given that McDonalds-MS is based just in the distribution of the lesions, even twins with the same underlying condition can be classified different[148]

Finally, the "exclusion of every other known disease" condition also creates problems. Rightfully classified MS patients can be rightfully classified out of the spectrum when their particular underlying problem is discovered. For example, neuromyelitis optica was previously considered MS and currently is not, even if it appears that the MS definition has not changed.

Currently there is no single diagnosis test for MS that is 100% sensitive and specific.[149][150]

Pathological and clinical definitions[edit]

McDonald criteria propose a clinical diagnosis based on a pathological definition, saying that the focus for diagnosis "remains on the objective demonstration of dissemination of lesions in both time and space" (DIT and DIS). But given that other diseases produce similar lesions, it is also required that those lesions cannot be explained by any other known disease.

This open definition present problems.[151] For example, before the discovery of anti-AQP4 in 2006, most optic-spinal MS patients were classified rightfully as MS. Currently they are classified as NMO. Both diagnosis are correct even though the definition has not (apparently) changed.

According to some pathologists, a pathological definition is required because clinical definitions have problems with differential diagnosis[152] and they always use a pathological definition on articles about post-mortem retrospective diagnosis, but for practitioners that need a diagnosis as soon as possible MS is often regarded as a pure clinical entity, defined simply by a positive result in the standard clinical case definition being then named "clinically definite MS" (CDMS, Poser) or simply "MS" (McDonald).[153]

Both definitions lead to different results. For example, confluent subpial cortical lesions are the most specific finding for MS, being exclusively present in MS patients.[154] but can only be detected post-mortem by an autopsy[155] Therefore, any other diagnosis method will have false positives.

Other meanings of MS[edit]

There is no known etiology for MS and therefore no etiology-based definition is possible. Comparison to a post-mortem retrospective diagnosis is possible, but useless to practitioners and short-term researchers, and it is not usually done. Therefore, all meanings for the words "Multiple Sclerosis" are somehow diffuse.

The pathological definition based on proven dissemination in time and space has problems. For example, it leaves situations like RIS (radiologically isolated syndrome) outside the MS spectrum because the lack of proof, even in the case that this condition later could shown the same pathogenic conditions than MS cases.[156]

Besides, usually the term "multiple sclerosis" is used to refer to the presence of the unknown underlying condition that produces the MS lesions instead to the mere presence of the lesions. The term MS is also used to refers to the process of developing the lesions.[157]

Some authors instead speak about the biological disease vs. its clinical presentation.[158]

Anyway, the precise meaning in each case can be normally deduced from the context.

Handling several clinical definitions[edit]

Given that several definitions of MS coexist, some authors are referring to them using whether CDMS for Poser positives, or McDonalds-MS with a prefix for McDonalds positives, including the release year in the prefix.[159]

CIS and conversion to MS[edit]

The 2010 revision of the McDonald criteria[160] allows the diagnosis of MS with only one proved lesion (CIS). Consistently, the later revision for the MS phenotypes in 2013 was forced to consider CIS as one of the MS phenotypes.[161]

Therefore, the former concept of "Conversion from CIS to MS", that was declared when a patient had a second MS attack, does not apply anymore. More accurate is now to speak about conversions from the CIS phenotype to other MS phenotype.[162]

See also[edit]

References[edit]

  1. ^ Fontaine B (2001). "[Borderline forms of multiple sclerosis]". Revue Neurologique (in French). 157 (8–9 Pt 2): 929–34. PMID 11787357.
  2. ^ Wingerchuk DM, Lucchinetti CF (2007). "Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis". Current Opinion in Neurology. 20 (3): 343–50. doi:10.1097/WCO.0b013e3280be58d8. PMID 17495631. S2CID 17386506.
  3. ^ Poser CM, Brinar VV (October 2007). "Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review". Acta Neurologica Scandinavica. 116 (4): 201–6. doi:10.1111/j.1600-0404.2007.00902.x. PMID 17824894. S2CID 44411472.
  4. ^ Weinshenker B, Miller D (1998). "Multiple sclerosis: one disease or many?". In Thompson AB, Siva A, Kesselring J (eds.). Frontiers in Multiple Sclerosis (2nd ed.). London: Taylor & Francis Group. pp. 37–46. ISBN 978-1-85317-506-0.
  5. ^ Hartung HP, Grossman RI (May 2001). "ADEM: distinct disease or part of the MS spectrum?". Neurology. 56 (10): 1257–60. doi:10.1212/WNL.56.10.1257. PMID 11376169.
  6. ^ Zabad RK, Stewart R, Healey KM (October 2017). "Pattern Recognition of the Multiple Sclerosis Syndrome". Brain Sciences. 7 (10): 138. doi:10.3390/brainsci7100138. PMC 5664065. PMID 29064441.
  7. ^ Fujihara, Kazuo (June 2019). "Neuromyelitis optica spectrum disorders". Current Opinion in Neurology. 32 (3): 385–394. doi:10.1097/WCO.0000000000000694. PMC 6522202. PMID 30893099.
  8. ^ a b c David Bargiela, Patrick F Chinnery, Mitochondria in neuroinflammation – Multiple sclerosis (MS), leber hereditary optic neuropathy (LHON) and LHON-MS, https://doi.org/10.1016/j.neulet.2017.06.051
  9. ^ a b Sinah Engel et al., PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders, January 2, 2020 [1]
  10. ^ a b Alnasser Alsukhni R, Jriekh Z, Aboras Y (2016). "Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 1–6. doi:10.1155/2016/1423131. PMC 5093248. PMID 27840642.CS1 maint: multiple names: authors list (link)
  11. ^ a b c Vicente LG; et al. (2016). "Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab". Neuro Oncol. 18: iv25. doi:10.1093/neuonc/now188.085.
  12. ^ a b c d Höftberger R, Leisser M, Bauer J, Lassmann H (Dec 2015). "Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis?". Acta Neuropathologica Communications. 3 (1): 80. doi:10.1186/s40478-015-0260-9. PMC 4670499. PMID 26637427.
  13. ^ a b Marzia Anita Lucia Romeo et al, Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer, Journal of Neurology, pp 1–4, 04 October 2019
  14. ^ a b c Lassman Hans (Feb 2010). "Acute disseminated encephalomyelitis and multiple sclerosis". Brain. 133 (2): 317–319. doi:10.1093/brain/awp342. PMID 20129937.
  15. ^ a b Alicja Kalinowska-Lyszczarz, Mahboobeh Fereidan-Esfahani, Yong Guo, Pathological findings in central nervous system demyelination associated with infliximab, https://doi.org/10.1177/1352458519894710
  16. ^ Lang K, Prüss H (2017). "Frequencies of neuronal autoantibodies in healthy controls. Estimation of disease specificity". Neurology: Neuroimmunology & Neuroinflammation. 4 (5): e386. doi:10.1212/NXI.0000000000000386. PMC 5515597. PMID 28761905.
  17. ^ Kusunoki, Susumu (2013). "Autoantibodies in neuroimmunological diseases; relevance of fine specificity". Experimental Neurology. 250: 219–220. doi:10.1016/j.expneurol.2013.10.009. PMID 24120752. S2CID 45173537.
  18. ^ Meagan Seay et al., Glial Fibrillary Acidic Protein Antibody: Another Antibodyin the Multiple Sclerosis Diagnostic Mix, Seay and Galetta:J Neuro-Ophthalmog. 2018; 38:276-284 [2]
  19. ^ Kazutoshi Sato Douglas; et al. (Feb 2014). "Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders". Neurology. 82 (6): 474–481. doi:10.1212/WNL.0000000000000101. PMC 3937859. PMID 24415568.
  20. ^ Weinshenker Brian G (2014). "The two faces of neuromyelitis optica". Neurology. 82 (6): 466–467. doi:10.1212/WNL.0000000000000114. PMID 24415570. S2CID 30860834.
  21. ^ a b Gahr M, Lauda F, Wigand ME, Connemann BJ, Rosenbohm A, Tumani H, Reindl M, Uzelac Z, Lewerenz J (2015). "Periventricular white matter lesion and incomplete MRZ reaction in a male patient with anti-N-methyl-D-aspartate receptor encephalitis presenting with dysphoric mania". BMJ Case Reports. 2015: bcr2014209075. doi:10.1136/bcr-2014-209075. PMC 4422915. PMID 25917068.
  22. ^ Li Y, Xie P, Lv F, et al. (2008). "Brain magnetic resonance imaging abnormalities in neuromyelitis optica". Acta Neurologica Scandinavica. 118 (4): 218–25. doi:10.1111/j.1600-0404.2008.01012.x. PMID 18384459. S2CID 22270592.
  23. ^ Wingerchuk, Dean (2006). "Neuromyelitis Optica (Devic's Syndrome)" (PDF). 2006 Rare Neuroimmunologic Disorders Symposium. Archived from the original (PDF) on 2006-09-25. Retrieved 2007-01-05.
  24. ^ Ikeda, Ken; Ito, Hirono; Hidaka, Takanobu; Takazawa, Takanori; Sekine, Tokinori; Yoshii, Yasuhiro; Hirayama, Takehisa; Kawabe, Kiyokazu; Kano, Osamu; Iwasaki, Yasuo (2011). "Repeated Non-enhancing Tumefactive Lesions in a Patient with a Neuromyelitis Optica Spectrum Disorder". Internal Medicine. 50 (9): 1061–1064. doi:10.2169/internalmedicine.50.4295. PMID 21532234.
  25. ^ Pröbstel AK; et al. (Mar 2015). "Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype". Journal of Neuroinflammation. 12 (1): 46. doi:10.1186/s12974-015-0256-1. PMC 4359547. PMID 25889963.
  26. ^ Spadaro Melania; et al. (2015). "Histopathology and clinical course of MOG-antibody-associated encephalomyelitis". Annals of Clinical and Translational Neurology. 2 (3): 295–301. doi:10.1002/acn3.164. PMC 4369279. PMID 25815356.
  27. ^ a b Spadaro M, et al. (2016). "Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis". Neurology: Neuroimmunology & Neuroinflammation. 3 (5): e257. doi:10.1212/NXI.0000000000000257. PMC 4949775. PMID 27458601.
  28. ^ a b c Reindl M, Di Pauli F, Rostásy K, Berger T (Aug 2013). "The spectrum of MOG autoantibody-associated demyelinating diseases". Nature Reviews Neurology. 9 (8): 455–61. doi:10.1038/nrneurol.2013.118. PMID 23797245. S2CID 7219279.
  29. ^ Spadaro Melania; et al. (2015). "Histopathology and clinical course of MOG-antibody-associated encephalomyelitis". Annals of Clinical and Translational Neurology. 2 (3): 295–301. doi:10.1002/acn3.164. PMC 4369279. PMID 25815356.
  30. ^ Baumann, M.; Hennes, E.M.; Schanda, K.; Karenfort, M.; Bajer-Kornek, B.; Diepold, K.; Fiedler, B.; Marquardt, I.; Strautmanis, J.; Vieker, S.; Reindl, M.; Rostásy, K. (2015). "OP65 – 3006: Clinical characteristics and neuroradiological findings in children with multiphasic demyelinating encephalomyelitis and MOG antibodies". European Journal of Paediatric Neurology. 19: S21. doi:10.1016/S1090-3798(15)30066-0.
  31. ^ Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, Brück W, Wildemann B (Feb 2016). "Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case". Multiple Sclerosis Journal. 22 (12): 1541–1549. doi:10.1177/1352458515622986. PMID 26869529. S2CID 1387384.
  32. ^ Kitagawa S, Osada T, Kaneko K, Takahashi T, Suzuki N, Nakahara J (Nov 2018). "Clinical analysis of opticospinal multiple sclerosis (OSMS) presentation detecting anti-myelin oligodendrocyte glycoprotein (MOG) antibody". Rinsho Shinkeigaku. 58 (12): 737–744. doi:10.5692/clinicalneurol.cn-001184. PMID 30487359.
  33. ^ Chalmoukou K; et al. (2015). "Recurrent Optic Neuritis (rON) is characterised by Anti-MOG Antibodies: A follow-up study". Neurology. 84 (14 Suppl P5): 274.
  34. ^ Rossman I (2015). "An 8 Year Old Girl with Chronic Inflammatory Optic Neuritis (CRION): the Youngest Reported Case to Date". Neurology. 84 (14): Supplement P7.015.
  35. ^ Chalmoukou K; Alexopoulos H; Akrivou S; Stathopoulos P; Reindl M; Dalakas MC (2015). "Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis". Neurology: Neuroimmunology & Neuroinflammation. 2 (4): e131. doi:10.1212/NXI.0000000000000131. PMC 4496630. PMID 26185777.
  36. ^ Navarro Canto L; et al. (2019). "Brain Atrophy in Relapsing Optic Neuritis is Associated with Crion Phenotype". Frontiers in Neurology. 10: 1157. doi:10.3389/fneur.2019.01157. PMC 6838209. PMID 31736862.
  37. ^ Silvia Tenembaum et al. Spectrum of MOG Autoantibody-Associated Inflammatory Diseases in Pediatric Patients, Neurology 2015; vol. 84 no. 14 Supplement I4-3A
  38. ^ Ya Y; et al. (2015). "Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD". Science China Life Sciences. 59 (12): 1270–1281. doi:10.1007/s11427-015-4997-y. PMC 5101174. PMID 26920678.
  39. ^ Marcus Vinicius, Magno Goncalves, Yara Dadalti Fragoso, The involvement of anti-neurofascin 155 antibodies in central and peripheral demyelinating diseases, Neuroimmunol Neuroinflammation, 8 Apr 2019;6:6.10.20517/2347-8659.2019.08
  40. ^ a b c Kira, Jun-Ichi; Yamasaki, Ryo; Ogata, Hidenori (2019). "Anti-neurofascin autoantibody and demyelination". Neurochemistry International. 130: 104360. doi:10.1016/j.neuint.2018.12.011. PMID 30582947.
  41. ^ Stich O, Perera S, Berger B, Jarius S, Wildemann B, Baumgartner A, Rauer S (March 2016). "Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis". Journal of the Neurological Sciences. 364: 29–32. doi:10.1016/j.jns.2016.03.004. PMID 27084211. S2CID 29204735.
  42. ^ Early research into a treatment for progressive MS
  43. ^ Williams, Isabelle; Uhlig, Holm H (7 October 2020). "Demyelination After Anti-TNF Therapy: Who is at Risk?". Journal of Crohn's and Colitis: jjaa144. doi:10.1093/ecco-jcc/jjaa144. PMID 33026456.
  44. ^ Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, Roemer SF, Thomsen KM, Mandrekar JN, Erickson BJ, Lucchinetti CF (2010). "Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis". Brain. 133 (2): 333–348. doi:10.1093/brain/awp321. PMC 2822631. PMID 20129932.
  45. ^ Nikoskelainen EK, Marttila RJ, Huoponen K, et al. (August 1995). "Leber's "plus": neurological abnormalities in patients with Leber's hereditary optic neuropathy". J. Neurol. Neurosurg. Psychiatry. 59 (2): 160–4. doi:10.1136/jnnp.59.2.160. PMC 485991. PMID 7629530.
  46. ^ cardiac arrythmia
  47. ^ Mayo Clinic: Multiple Sclerosis
  48. ^ Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Brück W (July 2008). "Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis". Brain. 131 (Pt 7): 1759–75. doi:10.1093/brain/awn098. PMC 2442427. PMID 18535080.
  49. ^ Given CA, Stevens BS, Lee C (1 January 2004). "The MRI appearance of tumefactive demyelinating lesions". American Journal of Roentgenology. 182 (1): 195–9. doi:10.2214/ajr.182.1.1820195. PMID 14684539.
  50. ^ Reindl M; Di Pauli F; Rostásy K; Berger T (August 2013). "The spectrum of MOG autoantibody-associated demyelinating diseases". Nature Reviews Neurology. 9 (8): 455–61. doi:10.1038/nrneurol.2013.118. PMID 23797245. S2CID 7219279.
  51. ^ a b Hardy, Todd A.; Reddel, Stephen W.; Barnett, Michael H.; Palace, Jacqueline; Lucchinetti, Claudia F.; Weinshenker, Brian G. (2016). "Atypical inflammatory demyelinating syndromes of the CNS". The Lancet Neurology. 15 (9): 967–981. doi:10.1016/S1474-4422(16)30043-6. PMID 27478954. S2CID 26341166.
  52. ^ Jiménez Arango JA, Uribe Uribe CS, Toro González G (2013). "Lesser-known myelin-related disorders: Focal tumour-like demyelinating lesions". Neurologia. 30 (2): 97–105. doi:10.1016/j.nrl.2013.06.004. PMID 24094691.
  53. ^ Garrido C, Levy-Gomes A, Teixeira J, Temudo T (2004). "Enfermedad de Schilder: dos nuevos casos y revisión de la bibliografía" [Schilder's disease: two new cases and a review of the literature]. Revista de Neurología (in Spanish). 39 (8): 734–8. doi:10.33588/rn.3908.2003023. PMID 15514902.
  54. ^ Afifi AK, Bell WE, Menezes AH, Moore SA (1994). "Myelinoclastic diffuse sclerosis (Schilder's disease): report of a case and review of the literature". Journal of Child Neurology. 9 (4): 398–403. CiteSeerX 10.1.1.1007.559. doi:10.1177/088307389400900412. PMID 7822732. S2CID 38765870.
  55. ^ Schmalstieg WF, Keegan BM, Weinshenker BG (Feb 2012). "Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion". Neurology. 78 (8): 540–4. doi:10.1212/WNL.0b013e318247cc8c. PMID 22323754. S2CID 52859541.
  56. ^ Lattanzi S (2012). "Solitary sclerosis: Progressive myelopathy from solitary demyelinating lesion". Neurology. 79 (4): 393, author reply 393. doi:10.1212/01.wnl.0000418061.10382.f7. PMID 22826546.
  57. ^ Ayrignac X, Carra-Dalliere C, Homeyer P, Labauge P (2013). "Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. A new entity?". Acta Neurologica Belgica. 113 (4): 533–4. doi:10.1007/s13760-013-0182-x. PMID 23358965. S2CID 17631796.
  58. ^ Trapp BD; Vignos M; Dudman J; Chang A; Fisher E; Staugaitis SM; Battapady H; Mork S; Ontaneda D; Jones SE; Fox RJ; Chen J; Nakamura K; Rudick RA (2018). "Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study". The Lancet Neurology. 17 (10): 870–884. doi:10.1016/S1474-4422(18)30245-X. PMC 6197820. PMID 30143361.
  59. ^ Vignos, Megan C., A histopathological and magnetic resonance imaging assessment of myelocortical MS: A new pathological variant, https://etd.ohiolink.edu/pg_10?0::NO:10:P10_ETD_SUBID:114418
  60. ^ Hendrickson M; Chang A; Fisher E; Staugaitis S; Fox R; Mork S; Trapp B (2013). "Myelocortical multiple sclerosis: a subgroup of multiple sclerosis patients with spinal cord and cortical demyelination". Multiple Sclerosis Journal. 19 (11): 366.
  61. ^ Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, Yoshiura T, Nakao Y, Ishizu T, Kira JI (2009). "Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese". Multiple Sclerosis Journal. 15 (7): 834–47. doi:10.1177/1352458509104595. PMID 19465451. S2CID 19372571.
  62. ^ Mercan Ö, Ülger Z, Handan Mısırlı C, Türkoğlu R (2018). "Opticospinal Multiple Sclerosis Clinical Course and Immunological Parameters". Experimed. 8 (2): 47–51. doi:10.26650/experimed.2018.18002.CS1 maint: multiple names: authors list (link)
  63. ^ Jie Ping Schee, Shanthi Viswanathan, Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum, MS Journal, May 17, 2018
  64. ^ O'Connor P, Marriott J (2010). "Differential Diagnosis and Diagnostic Criteria for Multiple Sclerosis: Application and Pitfalls" (PDF). In Hohlfeld R, Lucchinetti CF (eds.). Multiple sclerosis 3 (1st ed.). Philadelphia: Saunders Elsevier. ISBN 978-1-4160-6068-0.
  65. ^ Mihalova T, Kwong JL, Alachkar H, 214 Analysis of CSF IgG index, IgG synthesis and clinical presentation among CSF OCBs negative patients, Journal of Neurology, Neurosurgery & Psychiatry 2019;90:e54
  66. ^ Link H, Huang YM (2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. S2CID 22724352.
  67. ^ Imrell K, Landtblom AM, Hillert J, Masterman T (2006). "Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct". Neurology. 67 (6): 1062–1064. doi:10.1212/01.wnl.0000237343.93389.35. PMID 17000979. S2CID 21855273.
  68. ^ Zeman AZ, Kidd D, McLean BN, Kelly MA, Francis DA, Miller DH, Kendall BE, Rudge P, Thompson EJ, McDonald WI (1996). "A study of oligoclonal band negative multiple sclerosis". Journal of Neurology, Neurosurgery & Psychiatry. 60 (1): 27–30. doi:10.1136/jnnp.60.1.27. PMC 486185. PMID 8558146.
  69. ^ Li R, Patterson KR, Bar-Or A (2018). "Reassessing B cell contributions in multiple sclerosis". Nature Immunology. 19 (7): 696–707. doi:10.1038/s41590-018-0135-x. PMID 29925992. S2CID 49347759.CS1 maint: multiple names: authors list (link)
  70. ^ Casanova, Bonaventura; Lacruz, Laura; Villar, María Luisa; Domínguez, José Andrés; Gadea, María Carcelén; Gascón, Francisco; Mallada, Javier; Hervás, David; Simó-Castelló, María; Álvarez-Cermeño, José Carlos; Calles, Carmen; Olascoaga, Javier; Ramió-Torrentà, Lluís; Alcalá, Carmen; Cervelló, Angeles; Boscá, Isabel; Pérez-Mirallles, Francisco Carlos; Coret, Francisco (2018). "Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients". Neurological Sciences. 39 (8): 1423–1430. doi:10.1007/s10072-018-3442-y. PMID 29882169. S2CID 46954452.
  71. ^ Graner, Michael; Pointon, Tiffany; Manton, Sean; Green, Miyoko; Dennison, Kathryn; Davis, Mollie; Braiotta, Gino; Craft, Julia; Edwards, Taylor; Polonsky, Bailey; Fringuello, Anthony; Vollmer, Timothy; Yu, Xiaoli; Nait-Oumesmar, Brahim (21 February 2020). "Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides". PLOS ONE. 15 (2): e0228883. doi:10.1371/journal.pone.0228883. PMC 7034880. PMID 32084151.
  72. ^ Codjia, Pekes; Ayrignac, Xavier; Carra-Dalliere, Clarisse; Cohen, Mikael; Charif, Mahmoud; Lippi, Anais; Collongues, Nicolas; Corti, Lucas; De Seze, Jerome; Lebrun, Christine; Vukusic, Sandra; Durand-Dubief, Francoise; Labauge, Pierre; SFSEP OFSEP (2019). "Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases". Multiple Sclerosis and Related Disorders. 28: 109–116. doi:10.1016/j.msard.2018.12.022. PMID 30592992.
  73. ^ a b Ayrignac, X.; Menjot De Champfleur, N.; Menjot De Champfleur, S.; Carra-Dallière, C.; Deverdun, J.; Corlobe, A.; Labauge, P. (2016). "Brain magnetic resonance imaging helps to differentiate atypical multiple sclerosis with cavitary lesions and vanishing white matter disease". European Journal of Neurology. 23 (6): 995–1000. doi:10.1111/ene.12931. PMID 26727496. S2CID 3917307.
  74. ^ Wallner-Blazek M, Rovira A, Fillipp M; et al. (2013). "Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis". J Neurol. 260 (8): 260–2022. doi:10.1007/s00415-013-6918-y. PMID 23620065. S2CID 28377856.CS1 maint: multiple names: authors list (link)
  75. ^ a b Dobson, R.; Giovannoni, G. (2019). "Multiple sclerosis - a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. PMID 30300457.
  76. ^ a b Díaz C, Zarco LA, Rivera DM (May 2019). "Highly active multiple sclerosis: An update". Mult Scler Relat Disord. 30: 215–224. doi:10.1016/j.msard.2019.01.039. PMID 30822617.CS1 maint: multiple names: authors list (link)
  77. ^ Morcos, Yvette; Lee, Sang Min; Levin, Michael C. (2003). "A role for hypertrophic astrocytes and astrocyte precursors in a case of rapidly progressive multiple sclerosis". Multiple Sclerosis Journal. 9 (4): 332–341. doi:10.1191/1352458503ms931oa. PMID 12926837. S2CID 43651011.
  78. ^ Masaki K, Suzuki SO, Matsushita T, Matsuoka T, Imamura S, Yamasaki R, et al. (2013). "Connexin 43 Astrocytopathy Linked to Rapidly Progressive Multiple Sclerosis and Neuromyelitis Optica". PLOS ONE. 8 (8): e72919. Bibcode:2013PLoSO...872919M. doi:10.1371/journal.pone.0072919. PMC 3749992. PMID 23991165.
  79. ^ Seidi, Osheik, The Role of Therapeutic Plasma Exchange in Clinical Neurology, university of Khartoum, http://khartoumspace.uofk.edu/handle/123456789/19625
  80. ^ Broadley SA, et al. (2015). "A new era in the treatment of multiple sclerosis". Medical Journal of Australia. 203 (3): 139–141. doi:10.5694/mja14.01218. hdl:10536/DRO/DU:30080418. PMID 26224184. S2CID 10805065.
  81. ^ Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B (2012). "Potassium channel KIR4.1 as an immune target in multiple sclerosis". New England Journal of Medicine. 367 (2): 115–23. doi:10.1056/NEJMoa1110740. PMC 5131800. PMID 22784115.
  82. ^ Schneider R (2013). "Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis". Frontiers in Neurology. 4: 125. doi:10.3389/fneur.2013.00125. PMC 3759297. PMID 24032025.
  83. ^ Ayoglu, Burcu; Häggmark, Anna; Khademi, Mohsen; Olsson, Tomas; Uhlén, Mathias; Schwenk, Jochen M.; Nilsson, Peter (2013). "Autoantibody Profiling in Multiple Sclerosis Using Arrays of Human Protein Fragments". Molecular & Cellular Proteomics. 12 (9): 2657–2672. doi:10.1074/mcp.M112.026757. PMC 3769337. PMID 23732997.
  84. ^ Ayoglu, Burcu; Mitsios, Nicholas; Kockum, Ingrid; Khademi, Mohsen; Zandian, Arash; Sjöberg, Ronald; Forsström, Björn; Bredenberg, Johan; Lima Bomfim, Izaura; Holmgren, Erik; Grönlund, Hans; Guerreiro-Cacais, André Ortlieb; Abdelmagid, Nada; Uhlén, Mathias; Waterboer, Tim; Alfredsson, Lars; Mulder, Jan; Schwenk, Jochen M.; Olsson, Tomas; Nilsson, Peter (2016). "Anoctamin 2 identified as an autoimmune target in multiple sclerosis". Proceedings of the National Academy of Sciences. 113 (8): 2188–2193. Bibcode:2016PNAS..113.2188A. doi:10.1073/pnas.1518553113. PMC 4776531. PMID 26862169.
  85. ^ Tengvall, Katarina; Huang, Jesse; Hellström, Cecilia; Kammer, Patrick; Biström, Martin; Ayoglu, Burcu; Lima Bomfim, Izaura; Stridh, Pernilla; Butt, Julia; Brenner, Nicole; Michel, Angelika; Lundberg, Karin; Padyukov, Leonid; Lundberg, Ingrid E.; Svenungsson, Elisabet; Ernberg, Ingemar; Olafsson, Sigurgeir; Dilthey, Alexander T.; Hillert, Jan; Alfredsson, Lars; Sundström, Peter; Nilsson, Peter; Waterboer, Tim; Olsson, Tomas; Kockum, Ingrid (2019). "Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk". Proceedings of the National Academy of Sciences. 116 (34): 16955–16960. doi:10.1073/pnas.1902623116. PMC 6708327. PMID 31375628.
  86. ^ Belova AN, Grygorieva VN, Rasteryaeva MV, Ruina EA, Belova EM, Solovieva VS, Boyko AN (2019). "Anti-NMDAR encephalitis associated with relapsing optic neuritis: a case report and differential diagnosis". Zh Nevrol Psikhiatr Im S S Korsakova. 119 (10): 137–146. doi:10.17116/jnevro201911910137. PMID 31934999.CS1 maint: multiple names: authors list (link)
  87. ^ Baheerathan A; et al. (2017). "Antecedent anti-NMDA receptor encephalitis in two patients with multiple sclerosis" (PDF). Multiple Sclerosis and Related Disorders. 12: 20–22. doi:10.1016/j.msard.2016.12.009. PMID 28283100.
  88. ^ Flotillin-1/2 autoantibodies in patients with inflammatory disorders of the CNS, Sara Mariotto, Alberto Gajofatto, Daniela Alberti, Sabine Lederer, Salvatore Monaco, Sergio Ferrari, Romana Hoeftberger, Neurology, April 09, 2019; vol. 92 no. 15 Supplement P2.2-072, Print ISSN 0028-3878, Online ISSN 1526-632X, [3]
  89. ^ Koutsis, Georgios; Breza, Marianthi; Velonakis, Georgios; Tzartos, John; Kasselimis, Dimitrios; Kartanou, Chrisoula; Karavasilis, Efstratios; Tzanetakos, Dimitrios; Anagnostouli, Maria; Andreadou, Elisavet; Evangelopoulos, Maria-Eleftheria; Kilidireas, Constantinos; Potagas, Constantin; Panas, Marios; Karadima, Georgia (2019). "X linked Charcot-Marie-Tooth disease and multiple sclerosis: Emerging evidence for an association". Journal of Neurology, Neurosurgery & Psychiatry. 90 (2): 187–194. doi:10.1136/jnnp-2018-319014. PMID 30196252. S2CID 52175657.
  90. ^ Yu-Wai-Man P, Spyropoulos A, Duncan HJ, Guadagno JV, Chinnery PF (September 2016). "A multiple sclerosis-like disorder in patients with OPA1 mutations". Annals of Clinical and Translational Neurology. 3 (9): 723–9. doi:10.1002/acn3.323. PMC 5018584. PMID 27656661.
  91. ^ Vojdani A, Mukherjee PS, Berookhim J, Kharrazian D (2015). "Detection of antibodies against human and plant aquaporins in patients with multiple sclerosis". Autoimmune Diseases. 2015: 905208. doi:10.1155/2015/905208. PMC 4529886. PMID 26290755.
  92. ^ Baranova; Mikheeva; Buneva; Nevinsky (2019). "Antibodies from the Sera of Multiple Sclerosis Patients Efficiently Hydrolyze Five Histones". Biomolecules. 9 (11): 741. doi:10.3390/biom9110741. PMC 6920934. PMID 31731780.
  93. ^ Tzartos JS, Stergiou C, Kilidireas K, Zisimopoulou P, Thomaidis T, Tzartos SJ (2013). "Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders". PLOS ONE. 8 (9): e74773. Bibcode:2013PLoSO...874773T. doi:10.1371/journal.pone.0074773. PMC 3781161. PMID 24086369.CS1 maint: multiple names: authors list (link)
  94. ^ Michael Robers, Harlori Tokhie, Aimee Borazanci, N-Type Calcium Channel Antibody Encephalitis Coexisting With Multiple Sclerosis, American Academy of Neurology, vol. 90 no. 15 Supplement P5.397, ISSN: 0028-3878, Online ISSN: 1526-632X, April 9, 2018
  95. ^ Faergeman, S.L., Evans, H., Attfield, K.E. et al. A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death Dis 11, 303 (2020). https://doi.org/10.1038/s41419-020-2494-0
  96. ^ Birnbaum J; Hoke A; Lalji A; Calabresi P; Bhargava P; Casciola-Rosen L (2018). "Anti–Calponin 3 Autoantibodies: A Newly Identified Specificity in Patients With Sjögren's Syndrome". Arthritis & Rheumatology. 70 (10): 1610–1616. doi:10.1002/art.40550. PMID 29749720.
  97. ^ Zhang Y; et al. (2018). "Genetic variants regulate NR1H3 expression and contribute to multiple sclerosis risk". Journal of the Neurological Sciences. 390: 162–165. doi:10.1016/j.jns.2018.04.037. PMID 29801879. S2CID 44082278.
  98. ^ Yeo T; et al. (2019). "Classifying the antibody-negative NMO syndromes". Neurology: Neuroimmunology & Neuroinflammation. 6 (6): e626. doi:10.1212/NXI.0000000000000626. PMC 6865851. PMID 31659123.
  99. ^ Tohyama, Sarasa and Hung, Peter S.P. and Cheng, Joshua C. and Zhang, Jia Y. and Hodaie, Mojgan, Lesional Trigeminal Neuralgia - Clinical and Neuroimaging Definition of a New Syndrome (March 2, 2019). The Lancet preprints, available at SSRN: [4]
  100. ^ Minagar A, Jy W, Jimenez JJ, Alexander JS (2006). "Multiple sclerosis as a vascular disease". Neurological Research. 28 (3): 230–5. doi:10.1179/016164106X98080. PMID 16687046. S2CID 16896871.
  101. ^ "Chronic Fatigue Syndrome - Symptoms, Diagnosis, Treatment of Chronic Fatigue Syndrome". Health Information. New York Times. The following test results... are seen consistently...: Brain MRI showing swelling in the brain or destruction of part of the nerve cells (demyelination)
  102. ^ a b University of Zurich(2018, October 11). Link Between Gut Flora and Multiple Sclerosis Discovered. NeuroscienceNews. Retrieved October 11, 2018 from http://neurosciencenews.com/multiple-sclerosis-gut-flora-10003/
  103. ^ a b Planas R; Santos R; Tomas-Ojer P; Cruciani C; Lutterotti A; Faigle W; Schaeren-Wiemers N; Espejo C; Eixarch H; Pinilla C; Martin R; Sospedra M (2018). "GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosis" (PDF). Science Translational Medicine. 10 (462): eaat4301. doi:10.1126/scitranslmed.aat4301. PMID 30305453. S2CID 52959112.
  104. ^ a b Kotaro Ogawa et al., (2019) Next-generation sequencing identifies contribution of both class I and II HLA genes on susceptibility of multiple sclerosis in Japanese, Journal of Neuroinflammation, volume 16, 162
  105. ^ a b Wang Z, et al. (2016). "Nuclear Receptor NR1H3 in Familial Multiple Sclerosis". Neuron. 90 (5): 948–954. doi:10.1016/j.neuron.2016.04.039. PMC 5092154. PMID 27253448.
  106. ^ Hain HS, Hakonarson H (Jun 2016). "The Added Value of Family Material in the Discovery of Multiple Sclerosis Genes". Neuron. 90 (5): 905–6. doi:10.1016/j.neuron.2016.05.027. PMID 27253441.
  107. ^ a b Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA (2014). "Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice". Experimental Neurology. 261: 620–32. doi:10.1016/j.expneurol.2014.07.020. PMID 25111532. S2CID 21263405.
  108. ^ Ulloa Bianca; Alahiri Marwan; Liu Ying; Sadiq Saud (2015). "Cerebrospinal Fluid Haptoglobin (Hp) Levels are elevated in MS patients with progressive disease". Neurology. 84 (14): 213.
  109. ^ Elkjaer ML, Nawrocki A, Kacprowski T, et al. Molecular markers in the CSF proteome differentiate neuroinflammatory diseases. Research Square; 2020. DOI: 10.21203/rs.3.rs-19710/v1.
  110. ^ Single Cell Analysis of MS CSF B-Cells Show Significant Differences in Expansion Patterns and Gene Family Usage Between MS Subtypes (4673), Jonah Vernejoul, Francesca Cali, Jerry Lin, Saud Sadiq, Neurology Apr 2020, 94 (15 Supplement) 4673;
  111. ^ Vukusic S, Confavreux C (2003). "Primary and secondary progressive multiple sclerosis". Journal of the Neurological Sciences. 206 (2): 153–5. doi:10.1016/S0022-510X(02)00427-6. PMID 12559503. S2CID 19215860.
  112. ^ Dressel A, Kolb AK, Elitok E, Bitsch A, Bogumil T, Kitze B, Tumani H, Weber F (2006). "Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis". Acta Neurologica Scandinavica. 114 (6): 368–73. doi:10.1111/j.1600-0404.2006.00700.x. PMID 17083335. S2CID 71465403.
  113. ^ Villar LM; et al. (Aug 2014). "Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis". Annals of Neurology. 76 (2): 231–40. doi:10.1002/ana.24190. PMID 24909126. S2CID 16397501.
  114. ^ María Curbelo, Alejandra Martinez, Judith Steinberg and Adriana Carra, LOMS vs. Other Diseases: The Consequence of "To Be or Not To Be" (P3.081), Neurology April 5, 2016 vol. 86 no. 16 Supplement P3.081
  115. ^ Zwemmer JN, Bot JC, Jelles B, Barkhof F, Polman CH (April 2008). "At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only". Multiple Sclerosis Journal. 14 (3): 428–30. doi:10.1177/1352458507084591. PMID 18208890. S2CID 27178351.
  116. ^ Reinke SN, Broadhurst DL, Sykes BD, Baker GB, Catz I, Warren KG, Power C (2014). "Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis". Multiple Sclerosis Journal. 20 (10): 1396–400. doi:10.1177/1352458513516528. PMID 24468817. S2CID 24226475.
  117. ^ Balk L, Tewarie P, Killestein J, Polman C, Uitdehaag B, Petzold A (2014). "Disease course heterogeneity and OCT in multiple sclerosis". Multiple Sclerosis Journal. 20 (9): 1198–1206. doi:10.1177/1352458513518626. PMID 24402036. S2CID 7737278.
  118. ^ Poser CM, Brinar VV (2004). "The nature of multiple sclerosis". Clinical Neurology and Neurosurgery. 106 (3): 159–71. doi:10.1016/j.clineuro.2004.02.005. PMID 15177764. S2CID 23522920.
  119. ^ Liguori M, Qualtieri A, Tortorella C, Direnzo V, Bagalà A, et al. (2014). "Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of Neurodegeneration". PLOS ONE. 9 (8): e103984. Bibcode:2014PLoSO...9j3984L. doi:10.1371/journal.pone.0103984. PMC 4123901. PMID 25098164.
  120. ^ Ramos I. et al. Revealing underlying differences of NAWM from primary and secondary progressive MS (P4.404), Neurology April 18, 2017 vol. 88 no. 16 Supplement P4.404
  121. ^ Abdelhak A, Weber MS, Tumani H (2017). "Primary Progressive Multiple Sclerosis: Putting Together the Puzzle". Frontiers in Neurology. 8: 8–234. doi:10.3389/fneur.2017.00234. PMC 5449443. PMID 28620346.
  122. ^ Farina C; et al. (2019). "Loss of circulating CD8+ CD161high T cells in primary progressive multiple sclerosis". Front. Immunol. 10: 1922. doi:10.3389/fimmu.2019.01922. PMC 6702304. PMID 31474991.
  123. ^ Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R, Fetco D, Hussain M, O'Mahony J, Magalhaes S, McGowan M, Johnson T, Rajasekharan S, Narayanan S, Arnold DL, Weiner HL, Banwell B, Bar-Or A (2014). "Epitope spreading as an early pathogenic event in pediatric multiple sclerosis". Neurology. 83 (24): 2219–26. doi:10.1212/WNL.0000000000001066. PMC 4277672. PMID 25381299.
  124. ^ Dobson, R.; Giovannoni, G. (2019). "Multiple sclerosis - a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. PMID 30300457.
  125. ^ Lassmann, H. (2019). "Pathogenic Mechanisms Associated with Different Clinical Courses of Multiple Sclerosis". Frontiers in Immunology. 9: 3116. doi:10.3389/fimmu.2018.03116. PMC 6335289. PMID 30687321.
  126. ^ Hakiki B, Goretti B, Portaccio E, Zipoli V, Amato MP (2008). "'Subclinical MS': follow-up of four cases". European Journal of Neurology. 15 (8): 858–61. doi:10.1111/j.1468-1331.2008.02155.x. PMID 18507677. S2CID 27212599.
  127. ^ Lebrun C, Bensa C, Debouverie M, De Seze J, Wiertlievski S, Brochet B, Clavelou P, Brassat D, Labauge P, Roullet E (2008). "Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile". Journal of Neurology, Neurosurgery & Psychiatry. 79 (2): 195–8. doi:10.1136/jnnp.2006.108274. PMID 18202208. S2CID 11750372.
  128. ^ Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Mirabella M, Tonali PA, Batocchi AP (December 2008). "The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis". Journal of Neuroimmunology. 205 (1–2): 126–34. doi:10.1016/j.jneuroim.2008.09.003. PMID 18926576. S2CID 27303451.
  129. ^ Yuli Hou, Yujuan Jia, Jingtian Hou, Natural Course of Clinically Isolated Syndrome: A Longitudinal Analysis Using a Markov Model, 18 July 2018, Scientific Reports, volume 8, Article number: 10857 (2018)
  130. ^ Mackay Roland P.; Hirano Asao (1967). "Report of two clinically silent cases discovered at autopsy". Archives of Neurology. 17 (6): 588–600. doi:10.1001/archneur.1967.00470300030007. PMID 6054893.
  131. ^ Engell T (May 1989). "A clinical patho-anatomical study of clinically silent multiple sclerosis". Acta Neurologica Scandinavica. 79 (5): 428–30. doi:10.1111/j.1600-0404.1989.tb03811.x. PMID 2741673. S2CID 21581253.
  132. ^ Lebrun C, Kantarci OH, Siva A, Pelletier D, Okuda DT (2018). "Anomalies Characteristic of Central Nervous System Demyelination. Radiologically Isolated Syndrome". Neurologic Clinics. 36 (1): 59–68. doi:10.1016/j.ncl.2017.08.004. PMID 29157404.
  133. ^ Gabelic T, Ramasamy DP, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Hojnacki D, Ramanathan M, Zivadinov R (2014). "Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis". American Journal of Neuroradiology. 35 (1): 106–12. doi:10.3174/ajnr.A3653. PMID 23886745. Lay summarymsdiscovery.org.
  134. ^ Banwell B (2019). "Are children with multiple sclerosis really "old" adults". Multiple Sclerosis Journal. 25 (7): 888–890. doi:10.1177/1352458519841505. PMID 30945591.
  135. ^ Gabelic T, Weinstock-Guttman B, Melia R, Lincoff N, Masud MW, Kennedy C, Brinar V, Ramasamy DP, Carl E, Bergsland N, Ramanathan M, Zivadinov R (2013). "Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients". Clinical Neurology and Neurosurgery. 115 Suppl 1: S49–54. doi:10.1016/j.clineuro.2013.09.021. PMID 24321155. S2CID 41756033.
  136. ^ Rossi S; et al. (2015). "Subclinical central inflammation is risk for RIS and CIS conversion to MS". Multiple Sclerosis Journal. 21 (11): 1443–52. doi:10.1177/1352458514564482. PMID 25583841. S2CID 22377941.
  137. ^ Cramer; et al. (2015). "Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis". Brain. 138 (Pt 9): 2571–83. doi:10.1093/brain/awv203. PMC 4547053. PMID 26187333.
  138. ^ Cortese, Marianna, The timing of environmental risk factors and prodromal signs of multiple sclerosis, Doctoral thesis, 2017-12-18 [5]
  139. ^ Sazonov DV, Malkova NA, Bulatova EV, Riabukhina OV (2009). "[Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 109 (12): 76–9. PMID 20037526.
  140. ^ Rush, C. A.; MacLean, H. J.; Freedman, M. S. (2015). "Aggressive multiple sclerosis: Proposed definition and treatment algorithm". Nature Reviews Neurology. 11 (7): 379–89. doi:10.1038/nrneurol.2015.85. PMID 26032396. S2CID 205516534.
  141. ^ Maggliozzi, et al. (2018). "Inflammatory intrathecal profiles and cortical damage in multiple sclerosis". Annals of Neurology. 83 (4): 739–755. doi:10.1002/ana.25197. PMID 29518260. S2CID 5042430.
  142. ^ Díaz, Cindy; Zarco, Luis Alfonso; Rivera, Diego M. (2019). "Highly active multiple sclerosis: An update". Multiple Sclerosis and Related Disorders. 30: 215–224. doi:10.1016/j.msard.2019.01.039. PMID 30822617.
  143. ^ Konstantinos Notas et al., Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series, Multiple Sclerosis and Related Disorders, 11 November 2019, 101517
  144. ^ Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E (September 2008). "Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?". Neurology. 71 (14): 1090–3. CiteSeerX 10.1.1.594.9445. doi:10.1212/01.wnl.0000326896.66714.ae. PMID 18824673. S2CID 24065442.
  145. ^ Alroughani R, Boyko A (March 2018). "Pediatric multiple sclerosis: a review". BMC Neurology. 18 (1): 27. doi:10.1186/s12883-018-1026-3. PMC 5845207. PMID 29523094.
  146. ^ Rensburg SJ, Peeters AV, Toorn R, Schoeman J, Moremi KE, van Heerden CJ, Kotzee MJ (June 2019). "Identification of an iron-responsive subtype in two children diagnosed with relapsing-remitting multiple sclerosis using whole exome sequencing". Molecular Genetics and Metabolism Reports. 19: 100465. doi:10.1016/j.ymgmr.2019.100465. PMC 6434495. PMID 30963028.
  147. ^ Minagar, Alireza (2014). "Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment Options". Colloquium Series on Integrated Systems Physiology: From Molecule to Function. 6 (4): 1–117. doi:10.4199/C00116ED1V01Y201408ISP055. S2CID 71379237.
  148. ^ Susman, Ed (2016). "News from the ECTRIMS Congress". Neurology Today. 16 (21): 18–19. doi:10.1097/01.NT.0000508402.13786.97. S2CID 78597245.
  149. ^ Rovira, Àlex; Wattjes, Mike P.; Tintoré, Mar; Tur, Carmen; Yousry, Tarek A.; Sormani, Maria P.; De Stefano, Nicola; Filippi, Massimo; Auger, Cristina; Rocca, Maria A.; Barkhof, Frederik; Fazekas, Franz; Kappos, Ludwig; Polman, Chris; Miller, David; Montalban, Xavier (2015). "MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process". Nature Reviews Neurology. 11 (8): 471–482. doi:10.1038/nrneurol.2015.106. PMID 26149978.
  150. ^ Mistry N, Dixon J, Tallantyre E, Tench C, Abdel-Fahim R, Jaspan T, Morgan PS, Morris P, Evangelou N (May 2013). "Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain". JAMA Neurology. 70 (5): 623–8. doi:10.1001/jamaneurol.2013.1405. PMID 23529352.
  151. ^ Schippling, Sven (2017). "MRI for multiple sclerosis diagnosis and prognosis". Neurodegenerative Disease Management. 7 (6s): 27–29. doi:10.2217/nmt-2017-0038. PMID 29143579.
  152. ^ Lassmann H (2010). "Acute disseminated encephalomyelitis and multiple sclerosis". Brain. 133 (Pt 2): 317–9. doi:10.1093/brain/awp342. PMID 20129937.
  153. ^ McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis" (PDF). Annals of Neurology. 50 (1): 121–7. CiteSeerX 10.1.1.466.5368. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
  154. ^ Lassmann Hans (2014). "Multiple sclerosis: Lessons from molecular neuropathology". Experimental Neurology. 262: 2–7. doi:10.1016/j.expneurol.2013.12.003. PMID 24342027. S2CID 25337149.
  155. ^ Kutzelnigg Alexandra; et al. (2007). "Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis". Brain Pathology. 17 (1): 38–44. doi:10.1111/j.1750-3639.2006.00041.x. PMID 17493036. S2CID 38379112.
  156. ^ Lebrun, Christine; Kantarci, Orhun H.; Siva, Aksel; Pelletier, Daniel; Okuda, Darin T.; RISConsortium (2018). "Anomalies Characteristic of Central Nervous System Demyelination". Neurologic Clinics. 36 (1): 59–68. doi:10.1016/j.ncl.2017.08.004. PMID 29157404.
  157. ^ Dutta R, Trapp BD (2006). "[Pathology and definition of multiple sclerosis]". La Revue du Praticien (in French). 56 (12): 1293–8. PMID 16948216.
  158. ^ Quintana, F. J.; Patel, B.; Yeste, A.; Nyirenda, M.; Kenison, J.; Rahbari, R.; Fetco, D.; Hussain, M.; O'Mahony, J.; Magalhaes, S.; McGowan, M.; Johnson, T.; Rajasekharan, S.; Narayanan, S.; Arnold, D. L.; Weiner, H. L.; Banwell, B.; Bar-Or, A.; Canadian Pediatric Demyelinating Disease Network (2014). "Epitope spreading as an early pathogenic event in pediatric multiple sclerosis". Neurology. 83 (24): 2219–2226. doi:10.1212/WNL.0000000000001066. PMC 4277672. PMID 25381299.
  159. ^ Dalla Costa, Gloria; Martinelli, Vittorio; Sangalli, Francesca; Moiola, Lucia; Colombo, Bruno; Radaelli, Marta; Leocani, Letizia; Furlan, Roberto; Comi, Giancarlo (2019). "Prognostic value of serum neurofilaments in patients with clinically isolated syndromes". Neurology. 92 (7): e733–e741. doi:10.1212/WNL.0000000000006902. PMC 6382362. PMID 30635483.
  160. ^ Polman, CH; Reingold, SC; Banwell, B; Clanet, M; Cohen, JA; Filippi, M; Fujihara, K; Havrdova, E; Hutchinson, M; Kappos, L; Lublin, FD; Montalban, X; O'Connor, P; Sandberg-Wollheim, M; Thompson, AJ; Waubant, E; Weinshenker, B; Wolinsky, JS (February 2011). "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria". Annals of Neurology. 69 (2): 292–302. doi:10.1002/ana.22366. PMC 3084507. PMID 21387374.
  161. ^ Lublin, F. D.; Reingold, S. C.; Cohen, J. A.; Cutter, G. R.; Sorensen, P. S.; Thompson, A. J.; Wolinsky, J. S.; Balcer, L. J.; Banwell, B.; Barkhof, F.; Bebo, B.; Calabresi, P. A.; Clanet, M.; Comi, G.; Fox, R. J.; Freedman, M. S.; Goodman, A. D.; Inglese, M.; Kappos, L.; Kieseier, B. C.; Lincoln, J. A.; Lubetzki, C.; Miller, A. E.; Montalban, X.; O'Connor, P. W.; Petkau, J.; Pozzilli, C.; Rudick, R. A.; Sormani, M. P.; et al. (2014). "Defining the clinical course of multiple sclerosis: The 2013 revisions". Neurology. 83 (3): 278–286. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
  162. ^ Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, Thompson AJ, Miller DH (July 2002). "Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis". Annals of Neurology. 52 (1): 47–53. doi:10.1002/ana.10240. PMID 12112046. S2CID 24039151.